Feb 2 (Reuters) - Trillium Therapeutics Inc TRIL.TO :
* Trillium Therapeutics Inc - intends to provide an update on ongoing TTI-621 trials by year-end.
* Trillium Therapeutics Inc - in 2017, trillium is also planning to advance its second sirpafc fusion protein, TTI-622, into clinical testing. Source text for Eikon: ID:nCCN1Djwym Further company coverage: TRIL.TO